poguemahone
7 hours ago
Here goes my technical analysis: the closing price of $6.48 represents the lower channel of the band that extended through to $6.73. $6.73 represents the resistance zone, as this price has been tested, retested, and retreated. Bollinger bands and stochastic modeling indicate the price could go higher, but it certainly could go lower as well. The key to watch for is if the color is green, the price is higher, which then means it could go lower or remain unchanged, as traders generally want to make money. Look for the stock to go up or down, but it might also remain unchanged if buyers lack conviction. It’s too hard to call right now, so I’ll get back to you tomorrow at 4:30 to let you know what already happened.
123tom
8 hours ago
Looking at EW...
Like you said ,counting waves can be a little tricky. You can see 5 waves up, but also it could extend to 7 waves. I've even counted 9 waves in a finished pattern at times.
Sometimes it helps when I go back to the bottom and start over. I can clearly see the 1st upwave, from 3.25/3.40 bottom to finish peak around 4.50/4.60. As Wave 1
Wave 2 pulls back and holds support at 3.50/3.65/3.73.
Then we get the latest surging upwave that peaked at 6.80. This is the more difficult wave to analyze because depending on how you count it, could be a wave 3,4,and 5 finished.Or... it could be just one wave 3, you know ,like counting 1 of 5 of 3, 2 of 5 of 3, etc. The pullback around 6.40 is looking zig zaggy like a Wave 4.... so that's why I'm thinking the surge to 6.80 was only a Wave 3 , now sideways zig zag is wave 4, and we could anticipate wave 5 to target 7.60-8.40 area as a finished pattern.
RedShoulder
10 hours ago
Short Report just out: 07/15/2024 18,440,980
07/15/2024 18,440,980 3.45 802,783 22.97
06/28/2024 17,825,737 (14.89) 1,692,163 10.53
06/14/2024 20,944,467 (4.00) 1,071,745 19.54
05/31/2024 21,816,277 (0.20) 1,033,741 21.10
05/15/2024 21,860,442 2.68 1,029,913 21.23
https://nasdaqtrader.com/Trader.aspx?id=ShortInterest
nidan7500
14 hours ago
see below as evidence supporting Xenalives post:
Two of the most significant biomarkers found in Alzheimer’s are decreased glucose uptake and the accumulation of amyloid plaques in the brain. PET scans use different radioactive drugs, called radiotracers, to measure these biomarkers within the brain tissue of patients with cognitive impairment. FDG-PET is one of the most commonly used imaging techniques to diagnose Alzheimer’s. However, in recent years, several other radiotracers, such as florbetapir, have been developed to detect the deposition of amyloid plaques.
Recently, the effectiveness of amyloid imaging as a strategy for monitoring dementia symptoms has been called into question. While the presence of amyloid plaques in the brain is considered as being characteristic of Alzheimer’s, some studies have shown that large amounts of amyloid plaques were present in healthy, non-demented individuals. Conversely, recent clinical trials have shown that the intended removal of amyloid from the brains of patients with Alzheimer’s disease led to no change in, or even worsened, cognitive performance.
IMO, there is a massive pile of evidence which clearly contradicts FDA claims of any certain causal links . Why-how the FDA have continued w/this is baffling.
https://www.pennmedicine.org/news/news-releases/2019/august/measuring-brains-amyloid-buildup-less-effective-alzehimers-disease-compared-imaging-methods#:~:text=While%20the%20presence%20of%20amyloid,
XenaLives
15 hours ago
Plaque attack drugs will not work long term because plaque is a symptom, not a cause.
Fromm your link:
"About Buntanetap
Buntanetap (formerly known as Posiphen or ANVS401) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This improves synaptic transmission, axonal transport, and reduces neuroinflammation. Dysregulation of these pathways has been shown to cause nerve cell degeneration and ultimately nerve cell death. By targeting these pathways, buntanetap has the potential to reverse neurodegeneration in Alzheimer’s, Parkinson’s, and other neurodegenerative diseases, thereby aiming to restore brain function and improve the quality of life for patients."
XenaLives
16 hours ago
You must be kidding.....
1. Are there any STUDIES that show the connection of brain shrinkage to AD functional benefit? (Not anecdotal data, but serious studies). I doubt it.
2. Even if these studies exist -- are they for the similar parts of the brains, as AVXL's drug work?
This is basic science...
Brain atrophy is a loss of neurons that occurs in Alzheimer's disease and is a widely accepted biomarker for the disease. In Alzheimer's, brain atrophy is accelerated compared to the atrophy that occurs with age, even in people who are cognitively healthy. Alzheimer's disrupts the processes that are vital to neurons and their networks, including communication, metabolism, and repair. This damage can cause many neurons to stop functioning properly, lose connections with other neurons, and eventually die.
National Institute on Aging
What Happens to the Brain in Alzheimer's Disease?
Jan 19, 2024 — How does Alzheimer's affect the brain? The brain typically shrinks to some deg...
Alzheimer's Association
Brain Atrophy and B Vitamins - Alzheimer's Association
September 22, 2010. Brain atrophy involves the loss of neurons. Some degree of atrophy and...
ScienceDirect.com
Predicting brain atrophy from tau pathology: a summary of ...
Atrophy rates are higher in pre-symptomatic and symptomatic Alzheimer's patients than in h...
The medial temporal lobe (MTL) is the first region of the brain to show atrophy in Alzheimer's disease. Over time, there are four main patterns of atrophy in Alzheimer's disease:
Progressive hippocampal and cortical atrophy: 59% of patients
Progressive hippocampal atrophy only: 19% of patients
Progressive cortical atrophy only: 12% of patients
No atrophy in either region: 10% of patients
Symptoms of brain atrophy can vary depending on which part of the brain is damaged and can range from mild to severe. Some symptoms include:
Aphasia
Difficulty speaking or writing
Inability to understand the meaning of words
Dementia
Hallucinations
Loss of language
Memory problems
Mood and personality changes
Poor judgment
Seizures
This is for informational purposes only. For medical advice or diagnosis, consult a professional. Generative AI is experimental.
You don't have a clue when it comes to the science ... search this thread for the term "autophagy" and read the discussion.
You can also read this article:
https://www.nature.com/articles/s43587-021-00098-4